Co-administered drugs in the gastrointestinal lumen

Co-administered drugs in the gastrointestinal lumen refers to the environment and process where multiple pharmacological agents interact within the digestive tract prior to systemic absorption (FDA, 2020). This is not a discrete biological target like a protein or receptor, but a critical site for pharmacokinetic drug-drug interactions (DDIs) (StatPearls, 2023). These interactions often involve physicochemical processes such as chelation, where metal ions in one drug bind to another drug, or pH-mediated changes in solubility (Varma et al., 2010). For instance, proton pump inhibitors can raise gastric pH, thereby reducing the absorption of drugs that require an acidic environment for dissolution (PubMed, PMC2999439). Managing these interactions is essential in clinical practice to prevent therapeutic failure or unexpected toxicity resulting from altered drug exposure. It represents a significant challenge in polypharmacy, particularly in elderly populations or those with chronic conditions (NIH, 2021). Understanding the timing and chemical nature of these interactions allows for optimized dosing schedules, such as spacing administration times to ensure proper bioavailability (Goodman & Gilman, 2018).

Other names

Luminal drug-drug interactionsPhysicochemical drug interactionsGastrointestinal drug-drug interactionsAbsorption-level drug interactions

Mechanisms include chelation (forming insoluble complexes with multivalent cations), adsorption (binding to the surface of resins or charcoal), and alteration of gastric pH which affects the solubility and ionization of weak acids and bases (StatPearls, 2023; Varma et al., 2010).